2 news items
Reported Sunday, Fennec Pharmaceuticals And Norgine Inked An Exclusive Licensing Agreement To Commercialize PEDMARQSI In Europe, Australia, And New Zealand
FENC
18 Mar 24
in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
FENC
17 Mar 24
Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors
- Prev
- 1
- Next